BR112019000499A2 - radioligantes para imagiologia da enzima ido1 - Google Patents

radioligantes para imagiologia da enzima ido1

Info

Publication number
BR112019000499A2
BR112019000499A2 BR112019000499-8A BR112019000499A BR112019000499A2 BR 112019000499 A2 BR112019000499 A2 BR 112019000499A2 BR 112019000499 A BR112019000499 A BR 112019000499A BR 112019000499 A2 BR112019000499 A2 BR 112019000499A2
Authority
BR
Brazil
Prior art keywords
radioligents
oxide enzyme
oxide
imaging
enzyme imaging
Prior art date
Application number
BR112019000499-8A
Other languages
English (en)
Portuguese (pt)
Inventor
J. DONNELLY David
Lee COLE Erin
Charles BURRELL Richard
A. TURLEY Wesley
J. ALLENTOFF Alban
Arthur WALLACE Michael
Aaron Balog James
Huang Audris
Skinbjerg Mette
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112019000499A2 publication Critical patent/BR112019000499A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
BR112019000499-8A 2016-07-19 2017-07-18 radioligantes para imagiologia da enzima ido1 BR112019000499A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
US62/364,020 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (1)

Publication Number Publication Date
BR112019000499A2 true BR112019000499A2 (pt) 2019-04-24

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000499-8A BR112019000499A2 (pt) 2016-07-19 2017-07-18 radioligantes para imagiologia da enzima ido1

Country Status (12)

Country Link
US (2) US20190282714A1 (https=)
EP (1) EP3487516A1 (https=)
JP (1) JP6987840B2 (https=)
KR (1) KR102513886B1 (https=)
CN (1) CN109475594A (https=)
AU (1) AU2017298262B2 (https=)
BR (1) BR112019000499A2 (https=)
EA (1) EA039877B1 (https=)
IL (1) IL264187B (https=)
MX (1) MX2019000508A (https=)
SG (1) SG11201900336YA (https=)
WO (1) WO2018017529A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018039518A1 (en) * 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3645008A4 (en) * 2017-06-30 2020-12-09 Bristol-Myers Squibb Company SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PRODUCTION
EP3993507A1 (en) * 2017-11-21 2022-05-04 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Information transmission method, network device, and terminal device
BR112020010964A2 (pt) * 2017-12-05 2020-11-17 Glaxosmithkline Intellectual Property Development Limited moduladores da indolamina 2,3-dioxigenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
AU2011223883B2 (en) * 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
AU2017298262B2 (en) 2024-07-18
MX2019000508A (es) 2019-03-28
SG11201900336YA (en) 2019-02-27
EP3487516A1 (en) 2019-05-29
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
CN109475594A (zh) 2019-03-15
KR102513886B1 (ko) 2023-03-27
JP6987840B2 (ja) 2022-01-05
US20190282714A1 (en) 2019-09-19
IL264187B (en) 2021-06-30
US20220305144A1 (en) 2022-09-29
IL264187A (en) 2019-02-28
EA201990198A1 (ru) 2019-06-28
JP2019527225A (ja) 2019-09-26
CA3031079A1 (en) 2018-01-25
AU2017298262A1 (en) 2019-03-07
EA039877B1 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
BR112019000499A2 (pt) radioligantes para imagiologia da enzima ido1
BR112018008454A2 (pt) composição detergente que compreende variantes de amilase e protease
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
MX371497B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
MX2018016021A (es) Composiciones y metodos que comprenden variante de enzima lipolitica.
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
EA201691534A1 (ru) Лечение устойчивых угрей
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
BR112015010104A2 (pt) Variante de enzima termolisina, composição e método de limpeza
BR112012020693A8 (pt) Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EP3414328C0 (en) GLYCOPROTEIN CUTTING ENZYMES
BR112017009467A2 (pt) composição de limpeza
BR112017005248A2 (pt) estimuladores de sgc
BR112018003297A2 (pt) absorvente feminino com braçadeiras de barreira
AR111589A1 (es) Enzimas lactasas con propiedades mejoradas
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
BR112018013833A2 (pt) métodos de administração de hepcidina
BR112017018154A2 (pt) ?composição e composição sólida para os cuidados orais e método para a limpeza dos dentes?
PT3113778T (pt) A presente invenção refere-se ao uso de certos inibidores da enzima d-aminoácido oxidase na prevenção ou tratamento de desordens atáxicas, particularmente a ataxia de friedrich e ataxias espinocerebelares.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]